Clayton Dehn has been appointed executive director of Metabolic Diseases at Celerion. Mr. Dehn will lead the expansion of the company’s current capabilities that support early proof-of-concept for the development of diabetes, obesity, metabolic and cardio-metabolic interventions.   Mr. Dehn has 15 years of experience in drug development and has conducted thousands of glucose clamps (a measure of insulin sensitivity), bringing substantial expertise in a variety of metabolic research tools. He has...